J&J scratches AD itch by acquiring experimental eczema antibody for $1.25B

J&J will pick up Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion to acquire all assets related to NM26.

Related Keywords

Jersey ,David Urech ,David Lee ,Ambrx Biopharma ,Johnson ,Drug Administration ,Johnson Innovative Medicine ,Yellow Jersey Therapeutics ,Numab Therapeutics ,